Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

1.2K
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.2K
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

1.3K
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
1.3K
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

1.1K
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.1K
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

1.4K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.4K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

989
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
989
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

1.5K
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Coronary artery bypass grafting in a patient with severe diffuse lesion and calcifi cation of small-diameter coronary arteries (case report)].

Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery·2026
Same author

[Hospital and midterms outcomes after simultaneous carotid endarterectomy and coronary artery bypass grafting].

Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery·2026
Same author

[Shunting of coronary arteries less than 1.5 mm in diameter. Analytical review].

Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery·2025
Same author

[Photodynamic inactivation of antibiotic-resistant microflora of gunshot wounds under fluorescence control].

Khirurgiia·2025
Same author

[Patient selection for left ventricular assist device implantation. The main problems].

Terapevticheskii arkhiv·2024
Same author

Comparative study of treatment efficacy in severe intraepithelial squamous cell lesions and preinvasive cervical cancer by conization and chlorin e6-mediated fluorescence-assisted systemic photodynamic therapy.

Photodiagnosis and photodynamic therapy·2024
Same journal

[Outcomes of Surgical Correction of the Urethra in the Management of Postcoital Cystitis: A Systematic Review and Meta-Analysis].

Urologiia (Moscow, Russia : 1999)·2025
Same journal

[Use of Longidaza in chronic prostatitis: A systematic review and meta-analysis].

Urologiia (Moscow, Russia : 1999)·2025
Same journal

[Epidemiology, risk factors, diagnosis, and microbiology of suppurative pyelonephritis: a systematic review and meta-analysis, part 1].

Urologiia (Moscow, Russia : 1999)·2025
Same journal

[Endocrine and metabolic changes in prostate cancer patients after radical prostatectomy].

Urologiia (Moscow, Russia : 1999)·2025
Same journal

[Risks of acute kidney injury with intravascular administration of an iodine-containing contrast agent in patients with acute pyelonephritis].

Urologiia (Moscow, Russia : 1999)·2025
Same journal

[Pharmacological treatment of overactive bladder: the potential of anticholinergic therapy].

Urologiia (Moscow, Russia : 1999)·2025
See all related articles

Related Experiment Video

Updated: Nov 30, 2025

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

553

[Alpha1-adrenergic blockers therapy and sexual function].

A A Shiryaev1,2, A V Govorov1,2, A O Vasilyev1,2,3

  • 1Department of Urology of the Moscow State Medical-Dental University named after A.I. Evdokimov, Moscow, Russia.

Urologiia (Moscow, Russia : 1999)
|November 13, 2020
PubMed
Summary
This summary is machine-generated.

Benign prostatic hyperplasia (BPH) affects more older men. Alfuzosin, a 1-adrenergic blocker, improves urinary symptoms without harming sexual function, and may even enhance it.

Keywords:
1-adrenergic blockersalfuzosinbenign prostatic hyperplasiasexual dysfunction

More Related Videos

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
09:49

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy

Published on: December 28, 2021

3.7K

Related Experiment Videos

Last Updated: Nov 30, 2025

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

553
Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
09:49

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy

Published on: December 28, 2021

3.7K

Area of Science:

  • Urology
  • Geriatrics
  • Pharmacology

Background:

  • Increasing life expectancy and improved healthcare have led to a rise in benign prostatic hyperplasia (BPH) cases.
  • Quality of life and prevention of complications are key management goals for BPH.
  • Pharmacotherapy with 1-adrenergic blockers (1-AB) is a primary treatment for BPH symptoms and progression.

Purpose of the Study:

  • To evaluate the impact of 1-AB on sexual function in men with BPH.
  • To identify optimal 1-AB for maintaining or improving sexual health in BPH patients.
  • To assess alfuzosin's specific effects on sexual function in the context of BPH management.

Main Methods:

  • Review of current pharmacotherapy strategies for BPH.
  • Analysis of the side effect profiles of 1-AB, focusing on sexual dysfunction.
  • Comparative assessment of alfuzosin against other 1-AB regarding sexual function outcomes.

Main Results:

  • 1-AB therapy can cause sexual side effects in some patients.
  • Alfuzosin demonstrates a neutral or potentially beneficial effect on erectile and ejaculatory function.
  • Alfuzosin is a suitable choice for sexually active men with BPH or those experiencing sexual dysfunction with other 1-AB.

Conclusions:

  • Treatment choice for BPH should consider the impact on sexual function, especially in elderly men.
  • Alfuzosin offers an effective option for managing BPH symptoms while preserving or improving sexual health.
  • Alfuzosin is recommended as a first-line treatment for BPH, particularly for patients concerned about sexual side effects.